Incyclix Bio
From 1995 to 2009, Jay Strum worked at GlaxoSmithKline as a Director. In 2009, they joined G1 Therapeutics as the Chief Scientific Officer and held that position until 2020. In 2020, they joined Incyclix Bio as the Chief Scientific Officer, a position they still hold.
Jay Strum earned a Bachelor of Science/Arts degree in Biology and Chemistry from Western Carolina University, which they attended from 1982 to 1987. Following this, Jay pursued a PhD in Biochemistry at Wake Forest University from 1987 to 1993.
This person is not in any teams
Incyclix Bio
Incyclix Bio, LLC is a next-generation cell cycle control company, advancing precision treatments that target the aberrant proliferation driving many cancers. The company’s lead compound is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor nearing clinical stage. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers. Headquartered in Research Triangle Park, NC, Incyclix Bio is founded by pioneers in CDK inhibitor discovery, research and development.